Education
About Us
Working with TipRanks
Follow Us
Rhythm Pharmaceuticals (RYTM)
:RYTM
RYTM Stock Chart & Stats
$111.86
-$0.41(-0.68%)
At close: 4:00 PM EST
$111.86
-$0.41(-0.68%)
Day’s Range― - ―
52-Week Range$45.91 - $122.20
Previous CloseN/A
Volume91.33K
Average Volume (3M)850.35K
Market Cap
$7.50B
Enterprise Value$6.60B
Total Cash (Recent Filing)$416.05M
Total Debt (Recent Filing)$151.00M
Price to Earnings (P/E)―
Beta1.71
Next Earnings
Mar 04, 2026EPS Estimate
-0.82Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.82
Shares Outstanding66,736,050
10 Day Avg. Volume1,206,582
30 Day Avg. Volume850,354
Financial Highlights & Ratios
PEG Ratio-0.37
Price to Book (P/B)20.75
Price to Sales (P/S)26.24
P/FCF Ratio-29.98
Enterprise Value/Market Cap0.88
Enterprise Value/Revenue37.84
Enterprise Value/Gross Profit42.33
Enterprise Value/Ebitda-39.03
Forecast
1Y Price Target
$138.62Price Target Upside23.92% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering15
EPS Forecast (FY)-3.14
Revenue Forecast (FY)$187.97M
Bulls Say, Bears Say
Bulls Say
Clinical Trial ProgressRYTM shared positive preliminary data from their exploratory Ph2 study of setmelanotide in Prader-Willi Syndrome, a historically difficult-to-treat disease.
Regulatory ProgressImcivree is currently under regulatory review for acquired hypothalamic obesity with a high probability of approval and a strong commercial launch anticipated.
Safety ProfileSetmelanotide's safety profile remains clean with no reported serious adverse events or adverse events leading to discontinuation.
Bears Say
Approval TimelineFDA delayed the setmelanotide (SET) PDUFA for acquired hypothalamic obesity (HO) to 3/20/26 from 12/20/25.
Financial PerformanceThe company reported a 3Q25 net loss of $0.82 per share, moderately wider than the forecast for a net loss of $0.72 per share.
Regulatory DelaysThe PDUFA date for setmelanotide in hypothalamic obesity was extended by 3 months, seen as a minor setback.
Rhythm Pharmaceuticals News
RYTM FAQ
What was Rhythm Pharmaceuticals’s price range in the past 12 months?
Rhythm Pharmaceuticals lowest stock price was $45.91 and its highest was $122.20 in the past 12 months.
What is Rhythm Pharmaceuticals’s market cap?
Rhythm Pharmaceuticals’s market cap is $7.50B.
When is Rhythm Pharmaceuticals’s upcoming earnings report date?
Rhythm Pharmaceuticals’s upcoming earnings report date is Mar 04, 2026 which is in 75 days.
How were Rhythm Pharmaceuticals’s earnings last quarter?
Rhythm Pharmaceuticals released its earnings results on Nov 04, 2025. The company reported -$0.82 earnings per share for the quarter, missing the consensus estimate of -$0.708 by -$0.112.
Is Rhythm Pharmaceuticals overvalued?
According to Wall Street analysts Rhythm Pharmaceuticals’s price is currently Undervalued.
Does Rhythm Pharmaceuticals pay dividends?
Rhythm Pharmaceuticals does not currently pay dividends.
What is Rhythm Pharmaceuticals’s EPS estimate?
Rhythm Pharmaceuticals’s EPS estimate is -0.82.
How many shares outstanding does Rhythm Pharmaceuticals have?
Rhythm Pharmaceuticals has 66,736,050 shares outstanding.
What happened to Rhythm Pharmaceuticals’s price movement after its last earnings report?
Rhythm Pharmaceuticals reported an EPS of -$0.82 in its last earnings report, missing expectations of -$0.708. Following the earnings report the stock price went down -7.693%.
Which hedge fund is a major shareholder of Rhythm Pharmaceuticals?
Currently, no hedge funds are holding shares in RYTM
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Rhythm Pharmaceuticals Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$138.62 (23.92% Upside)
$138.62 (23.92% Upside)
Blogger Sentiment
Bullish
RYTM Sentiment 70%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Increased
By 123.8K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Positive
Last 7 Days ▲ 7.1%
Last 30 Days ▲ 7.6%
Last 30 Days ▲ 7.6%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
96.93%
12-Months-Change
Fundamentals
Return on Equity
-240.36%
Trailing 12-Months
Asset Growth
39.41%
Trailing 12-Months
Company Description
Rhythm Pharmaceuticals
Rhythm Pharmaceuticals, Inc. is a biotechnology company focused on developing innovative therapeutics for the treatment of rare genetic disorders of obesity. The company primarily operates in the healthcare sector, specifically within the pharmaceutical industry, and is known for its proprietary product, setmelanotide, which targets the melanocortin-4 receptor pathway to address obesity caused by genetic deficiencies. Rhythm is dedicated to advancing the understanding of genetic obesity and aims to provide effective solutions for patients with rare obesity syndromes.
RYTM Company Deck
RYTM Earnings Call
Q3 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
Rhythm Pharmaceuticals demonstrated strong revenue growth and regulatory progress, particularly for IMCIVREE in hypothalamic obesity. While international revenue faced challenges, the company's successful equity offering and promising data in BBS highlight a positive outlook. R&D costs are rising, but the overall sentiment remains optimistic.View all RYTM earnings summariesRYTM Stock 12 Month Forecast
Average Price Target
$138.62
▲(23.92% Upside)
Technical Analysis
Cytokinetics
―
TG Therapeutics
―
Legend Biotech
―
Avidity Biosciences
―
Abivax SA Sponsored ADR
―
Ownership Overview
Currently, No data available
---